Protein Summary
Core component of multiple cullin-RING-based E3 ubiquitin-protein ligase complexes which mediate the ubiquitination of target proteins. As a scaffold protein may contribute to catalysis through positioning of the substrate and the ubiquitin-conjugating enzyme. The E3 ubiquitin-protein ligase activity of the complex is dependent on the neddylation of the cullin subunit and is inhibited by the association of the deneddylated cullin subunit with TIP120A/CAND1. The functional specificity of the E3 ubiquitin-protein ligase complex depends on the variable substrate recognition component. DCX(DET1-COP1) directs ubiquitination of JUN. DCX(DDB2) directs ubiquitination of XPC. DCX(DDB2) ubiquitinates histones H3-H4 and is required for efficient histone deposition during replication-coupled (H3.1) and replication-independent (H3.3) nucleosome assembly, probably by facilitating the transfer of H3 from ASF1A/ASF1B to other chaperones involved in histone deposition. DCX(DTL) plays a role in PCNA-dep ...more
- ENST00000375440
- ENSP00000364589
- ENSG00000139842
- ENST00000375441
- ENSP00000364590
- ENST00000451881
- ENSP00000389118
- ENST00000617546
- ENSP00000481782
Most Knowledge About | Knowledge Value
(0 to 1 scale) | ||
---|---|---|---|
virus perturbation | 0.98 | ||
transcription factor binding site profile | 0.9 | ||
biological process | 0.86 | ||
protein domain | 0.85 | ||
protein complex | 0.84 | ||
Protein Classes
IDG Development Level Summary
These are targets about which virtually nothing is known. They do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 119.43 (req: < 5)
Gene RIFs: 110 (req: <= 3)
Antibodies: 357 (req: <= 50)
These targets do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 119.43 (req: >= 5)
Gene RIFs: 110 (req: > 3)
Antibodies: 357 (req: > 50)
- OR - satisfy the following criterion:
Gene Ontology Terms: 28
Target has at least one ChEMBL compound with an activity cutoff of < 30 nM - AND - satisfies the preceding conditions
Active Ligands: 9
Target has at least one approved drug - AND - satisfies the preceding conditions
Active Drug: 0